Novartis Reports Results of Dual regimen in P-III COMBI-AD Study for Patients with Stage III Melanoma

 Novartis Reports Results of Dual regimen in P-III COMBI-AD Study for Patients with Stage III Melanoma

Novartis Reports Results of Dual regimen in P-III COMBI-AD Study for Patients with Stage III Melanoma

Shots:

  • The P-III COMBI-AD study involves assessing of Tafinlar (dabrafenib, 150mg, bid) + Mekinist (trametinib, 2mg, qd) vs two PBOs in patients with stage III, BRAF V600E/K-mutant melanoma without prior anticancer therapy for up to 1year
  • Results: alive and relapse-free patients @5yrs. (52% vs36%); 49% reduction in risk of relapse or death; m-REF (not reached vs 16.6mos.); DMFS rate (65% vs 54%); @3yrs. OS rate  (86% vs 77%). During the extended follow-up, all patients had completed therapy with no difference in rate or severity of SAEs reported during the follow-up period
  • Tafinlar and Mekinist are prescription therapies, used in combination to treat melanoma: that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and has a certain type of abnormal “BRAF” (V600E or V600K mutation-positive) gene

Click here ­to­ read full press release/ article | Ref: Novartis | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post